0H79 Analyst Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0H79 Stock 12 Month Forecast
Average Price Target
―| Highest Price Target$200.00 | Average Price Target$156.40 | Lowest Price Target$120.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$120
Buy
―
Reiterated
09/03/26
UBS
$130
Buy
―
Reiterated
09/01/26
TD Cowen
―
Buy
―
Reiterated
08/26/26
Piper Sandler
$180
Buy
―
Reiterated
08/17/26
LifeSci Capital
$125→$175
Buy
―
Reiterated
08/15/26
Barclays
$160
Buy
―
Reiterated
08/11/26
Wedbush
$165
Buy
―
Reiterated
08/11/26
Jefferies
$133
Buy
―
Reiterated
08/11/26
BTIG
$151
Buy
―
Reiterated
08/10/26
Guggenheim
$200
Buy
―
Reiterated
08/10/26
Stifel Nicolaus
$150
Buy
―
Reiterated
06/29/26
Leerink Partners
―
Buy
―
Reiterated
06/02/26
Clear Street
$71→$131
Buy
―
Reiterated
04/27/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$120
Buy
―
Reiterated
09/03/26
UBS
$130
Buy
―
Reiterated
09/01/26
TD Cowen
―
Buy
―
Reiterated
08/26/26
Piper Sandler
$180
Buy
―
Reiterated
08/17/26
LifeSci Capital
$125→$175
Buy
―
Reiterated
08/15/26
Barclays
$160
Buy
―
Reiterated
08/11/26
Wedbush
$165
Buy
―
Reiterated
08/11/26
Jefferies
$133
Buy
―
Reiterated
08/11/26
BTIG
$151
Buy
―
Reiterated
08/10/26
Guggenheim
$200
Buy
―
Reiterated
08/10/26
Stifel Nicolaus
$150
Buy
―
Reiterated
06/29/26
Leerink Partners
―
Buy
―
Reiterated
06/02/26
Clear Street
$71→$131
Buy
―
Reiterated
04/27/26
Best Analysts Covering Oruka Therapeutics
3 Months
Success Rate
10/11 ratings generated profit
Average Return
+56.69%
Copying Julian Harrison's trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +56.69% per trade.
1 Year
Success Rate
11/12 ratings generated profit
Average Return
+266.64%
Copying David Risinger's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +266.64% per trade.
2 Years
Success Rate
12/12 ratings generated profit
Average Return
+409.57%
Copying David Risinger's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +409.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0H79 Analyst Recommendation Trends
Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
26
24
14
13
9
Buy
10
9
4
7
7
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
33
18
20
16
Each month's total comprises the sum of three months' worth of ratings.
0H79 Financial Forecast
0H79 Stock Forecast FAQ
What is GB:0H79’s average 12-month price target, according to analysts?
Based on analyst ratings, Oruka Therapeutics’s 12-month average price target is 156.40.
What is GB:0H79’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for GB:0H79, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Oruka Therapeutics a Buy, Sell or Hold?
Oruka Therapeutics has a consensus rating of Strong Buy, which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is Oruka Therapeutics’s share price target?
The average share price target for Oruka Therapeutics is 156.40. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $200.00 ,and the lowest forecast is $120.00. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is $200.00 ,and the lowest forecast is $120.00. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about Oruka Therapeutics?
Oruka Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of Oruka Therapeutics?
To buy shares of GB:0H79, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.